Healthcare / Medical DevicesTaipei Exchange
$30.95
-1.05 (-3.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-3.2M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.0%
↓Gross Margin
31.0%
↓Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.9%
FCF CAGR
—
FCF margin
-0.6%
FCF / Net income
0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $501.5M · net income $-70.3M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $501.5M | $501.5M | $768.3M | $616.1M | $434.8M |
| Net Income | $-70.3M | $-70.3M | $73.2M | $46.7M | $33.4M |
| EBITDA | $-45.9M | $-45.9M | $131.2M | $116.2M | $99.0M |
| EPS | — | — | 1.89 | 1.28 | 0.90 |
| Gross Margin | 31.0% | 31.0% | 43.0% | 47.0% | 42.4% |
| Operating Margin | -14.8% | -14.8% | 14.7% | 10.6% | 10.8% |
| Net Margin | -14.0% | -14.0% | 9.5% | 7.6% | 7.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.43 | 0.43 | 0.40 | 1.02 | 0.71 |
| Current Ratio | 3.28 | 3.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $9.1M | $-155.7M | $84.6M |
| Returns | |||||
| ROE | -13.0% | -13.0% | 11.7% | 13.5% | 11.0% |
| Valuation | |||||
| P/E | — | — | 35.00 | 50.66 | 25.71 |
| EV/EBITDA | — | — | 20.22 | 22.77 | 9.81 |
| P/B | 2.26 | 2.26 | 4.10 | 6.84 | 2.83 |
| Growth & Yield | |||||
| Revenue Growth | -34.7% | -34.7% | 24.7% | 41.7% | — |
| EPS Growth | — | — | 48.2% | 41.0% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.9%
Start / end P/E
n/dx → n/dx
EPS bridge
1.89 → n/d
Residual
-41.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.